• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

RADIOTHERAPY GRANT

AlphaMed Inc. announced that it received a $500,000 two-year STTR Phase II grant award from the National Cancer Institute to further develop a targeted radiotherapy for metastatic melanoma.

Related Videos
Related Content
Understanding and Treating Pediatric AD Inside and Out
March 4th 2025

Understanding and Treating Pediatric AD Inside and Out

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Reviewing Complex Cases: Topicals for Pediatric AD
February 25th 2025

Reviewing Complex Cases: Topicals for Pediatric AD

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Phase 3 Trial Supports Roflumilast for Pediatric AD
February 24th 2025

Phase 3 Trial Supports Roflumilast for Pediatric AD

Ethical Considerations and Guidance of Cosmeceuticals in Pediatric Care
February 24th 2025

Ethical Considerations and Guidance of Cosmeceuticals in Pediatric Care

© 2025 MJH Life Sciences

All rights reserved.